MassDevice Q&A
Q&A Features
11/21/2011
by
Brad Perriello
Sanovas CEO Larry Gerrans on Sanovas Inc.'s breakthrough catheter-based platform for treating lung disease and why he thinks it's a game-changer.
The numbers on pulmonary disease in the U.S are staggering – more than 203,000 people were diagnosed in 2007 alone, according to the Centers for Disease Control, which lists nearly 160,000 lung cancer deaths for that year.
Add in other pulmonary afflictions like chronic obstructive pulmonary disease (126,000 deaths in 2005, according to the CDC) and the numbers pass from staggering to mind-boggling.
That's the space that...
11/16/2011
by
Brian Johnson
MassDevice talks with Edwards Lifesciences CEO Michael Mussallem about why the medical device industry is a good fit for him and the biggest mistake of his career.
If the good people of Orange County felt a gale force wind a few weeks back, it may have been a sigh of relief coming from the Irvine, Calif. headquarters of Edwards Lifesciences Corp. (NYSE:EW) after the FDA finally gave a much-anticipated green light to the company's Sapien transcatheter aortic valve.
Edwards had been hanging fire since July, when an FDA...
10/31/2011
by
Arezu Sarvestani
Capsule Tech's newly appointed North America president Stuart Long tells MassDevice about the company's surging growth and what it means to be a "middleware" service provider.
Click to play
When Stuart Long accepted the keys to the...
10/17/2011
by
Arezu Sarvestani
J. Raymond Elliott left an indelible mark on med-tech goliath Boston Scientific during two years in the corner office. As he passes the torch to interim CEO Hank Kucheman, MassDevice looks back on one of the most boisterous CEOs in the device space.
In two years in the corner office at Boston Scientific Corp. (NYSE:BSX), J. Raymond Elliott left an indelible stamp on the medical device goliath. As he steps down today, handing the keys over to interim CEO Hank Kucheman, he leaves some mighty big shoes to fill.
During his 26-month tenure, Elliott reduced the company's workforce by more than 2,200...
10/12/2011
by
MassDevice staff
AccuVein CEO Ron Goldman tells MassDevice about his firm's hand-held vascular imaging technology.
Venipuncture – drawing blood or establishing an intravenous feed – is the most common invasive medical procedure. For many patients, it's a painful exercise in frustration when clinicians struggle to find a blood vessel, sometimes requiring multiple needle sticks.
AccuVein and CEO Ron Goldman aim to change all that with the company's AV300 vascular illumination device. The wireless, handheld module uses a pair of lasers to paint a patient's arm with light, making...
10/05/2011
by
Brian Johnson
Stu Randle, CEO of GI Dynamics, discusses the company's recent Australian IPO in an interview with MassDevice.
GI Dynamics (ASX:GID) has been the talk of the medical device industry lately.
The Lexington, Mass.-based obesity and Type II diabetes treatment company pulled off one of the summer's funding coups, pocketing $86 million with an initial public offering on the Australian stock market. The IPO, the largest on the Australian Stock Exchange in 2011, netted the company enough capital...
RECENT BLOG POSTS
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
- Heart Rhythm Society 2013 Scientific Session wrap-up
- Physician blogger insights on social media
